COMMENTARY

Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?

February 6, 2006
Paul KingMcIntyre Harbin & Kingpking@mhk-law.comPart II: OwnershipIn the last issue, we discussed Professor Ochiai's inventorship issue raised in the Prograf legal action case in Japan, and how such an issue would be handled in a US lawsuit. In this issue,…

To read the full story

COMMENTARY

By Sakura Kono

Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…

A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Philip Carrigan

In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…